Literature DB >> 16330724

Hippocampal myo-inositol and cognitive ability in adults with Down syndrome: an in vivo proton magnetic resonance spectroscopy study.

Felix Beacher1, Andy Simmons, Eileen Daly, Verinder Prasher, Claire Adams, Maria Luisa Margallo-Lana, Robin Morris, Simon Lovestone, Kieran Murphy, Declan G M Murphy.   

Abstract

CONTEXT: Down syndrome (DS) is the most common genetic cause of mental retardation. However, the biological determinants of this are poorly understood. The serum sodium/myo-inositol cotransporter gene is located on chromosome 21, and myo-inositol affects neuronal survival and function. Nevertheless, few in vivo studies have examined the role of myo-inositol in DS.
OBJECTIVE: To determine if people with DS have significant differences in brain myo-inositol concentration from controls and if, within people with DS, this is related to cognitive ability.
DESIGN: A case-control study.
SETTING: Outpatient. PARTICIPANTS: The sample was composed of 38 adults with DS without dementia (age range, 18-66 years) and 42 healthy controls (age range, 19-66 years). The DS and control groups did not differ significantly in age, sex, ethnic origin, apolipoprotein E status, or handedness. MAIN OUTCOME MEASURES: Hippocampal myo-inositol concentration and cognitive performance, as measured by the Cambridge Cognitive Examination.
RESULTS: Hippocampal myo-inositol concentration was significantly higher in people with DS than in controls (P = .006), and within people with DS, increased myo-inositol concentration was significantly negatively correlated with overall cognitive ability (P = .04).
CONCLUSIONS: Adults with DS have a significantly increased brain concentration of myo-inositol, and this is associated with reduced cognitive ability. Future studies are required to relate myo-inositol concentration in people with DS to brain development and increased risk for developing Alzheimer disease.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16330724     DOI: 10.1001/archpsyc.62.12.1360

Source DB:  PubMed          Journal:  Arch Gen Psychiatry        ISSN: 0003-990X


  17 in total

1.  Association of Myoinositol Transporters with Schizophrenia and Bipolar Disorder: Evidence from Human and Animal Studies.

Authors:  Marquis P Vawter; Abdul Rezzak Hamzeh; Edgar Muradyan; Olivier Civelli; Geoffrey W Abbott; Amal Alachkar
Journal:  Mol Neuropsychiatry       Date:  2019-08-08

Review 2.  Improving Memory and Cognition in Individuals with Down Syndrome.

Authors:  Michael S Rafii
Journal:  CNS Drugs       Date:  2016-07       Impact factor: 5.749

3.  Knockdown of Myo-Inositol Transporter SMIT1 Normalizes Cholinergic and Glutamatergic Function in an Immortalized Cell Line Established from the Cerebral Cortex of a Trisomy 16 Fetal Mouse, an Animal Model of Human Trisomy 21 (Down Syndrome).

Authors:  Ana María Cárdenas; Paola Fernández-Olivares; Ignacio Díaz-Franulic; Arlek M González-Jamett; Takeshi Shimahara; Juan Segura-Aguilar; Raúl Caviedes; Pablo Caviedes
Journal:  Neurotox Res       Date:  2017-07-10       Impact factor: 3.911

4.  Differential methylation of the gene encoding myo-inositol 3-phosphate synthase (Isyna1) in rat tissues.

Authors:  Ratnam S Seelan; M Michele Pisano; Robert M Greene; Manuel F Casanova; Ranga N Parthasarathy
Journal:  Epigenomics       Date:  2011-02       Impact factor: 4.778

Review 5.  Molecular genetic analysis of Down syndrome.

Authors:  David Patterson
Journal:  Hum Genet       Date:  2009-06-13       Impact factor: 4.132

6.  Proton magnetic resonance spectroscopy in 22q11 deletion syndrome.

Authors:  Fabiana da Silva Alves; Erik Boot; Nicole Schmitz; Aart Nederveen; Jacob Vorstman; Christina Lavini; Petra J Pouwels; Petra Pouwels; Lieuwe de Haan; Don Linszen; Therese van Amelsvoort
Journal:  PLoS One       Date:  2011-06-30       Impact factor: 3.240

7.  A new cognitive evaluation battery for Down syndrome and its relevance for clinical trials.

Authors:  Susana de Sola; Rafael de la Torre; Gonzalo Sánchez-Benavides; Bessy Benejam; Aida Cuenca-Royo; Laura Del Hoyo; Joan Rodríguez; Silvina Catuara-Solarz; Judit Sanchez-Gutierrez; Ivan Dueñas-Espin; Gimena Hernandez; Jordi Peña-Casanova; Klaus Langohr; Sebastia Videla; Henry Blehaut; Magi Farre; Mara Dierssen
Journal:  Front Psychol       Date:  2015-06-04

8.  Hippocampal glutamate-glutamine (Glx) in adults with Down syndrome: a preliminary study using in vivo proton magnetic resonance spectroscopy ((1)H MRS).

Authors:  Giles My Tan; Felix Beacher; Eileen Daly; Jamie Horder; Verinder Prasher; Maria-Luisa Hanney; Robin Morris; Simon Lovestone; Kieran C Murphy; Andrew Simmons; Declan Gm Murphy
Journal:  J Neurodev Disord       Date:  2014-11-27       Impact factor: 4.025

9.  Abnormal brain synchrony in Down Syndrome.

Authors:  Jeffrey S Anderson; Jared A Nielsen; Michael A Ferguson; Melissa C Burback; Elizabeth T Cox; Li Dai; Guido Gerig; Jamie O Edgin; Julie R Korenberg
Journal:  Neuroimage Clin       Date:  2013-05-24       Impact factor: 4.881

Review 10.  Inositols Depletion and Resistance: Principal Mechanisms and Therapeutic Strategies.

Authors:  Elisa Lepore; Rosa Lauretta; Marta Bianchini; Marilda Mormando; Cherubino Di Lorenzo; Vittorio Unfer
Journal:  Int J Mol Sci       Date:  2021-06-24       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.